TREXIMET Drug Patent Profile

When do Treximet patents expire, and when can generic versions of Treximet launch?

Treximet is a drug marketed by Currax and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has sixteen patent family members in fourteen countries.

The generic ingredient in TREXIMET is naproxen sodium; sumatriptan succinate. There are forty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the naproxen sodium; sumatriptan succinate profile page.

DrugPatentWatch^® Generic Entry Outlook for Treximet

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TREXIMET

International Patents:	16
US Patents:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TREXIMET

Paragraph IV (Patent) Challenges for TREXIMET

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TREXIMET	Tablets	naproxen sodium; sumatriptan succinate	500 mg/85 mg	021926	1	2008-07-23

US Patents and Regulatory Information for TREXIMET

TREXIMET is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Currax	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-002	May 14, 2015		DISCN	Yes	No					Y
Currax	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-001	Apr 15, 2008	AB	RX	Yes	Yes					Y

International Patents for TREXIMET

See the table below for patents covering TREXIMET around the world.

Country	Patent Number	Title	Estimated Expiration
Philippines	24117	AN INDOLE DERIVATIVE
Luxembourg	86032
Hungary	T40077
Greece	851850
Jordan	1379
Japan	3712420

Supplementary Protection Certificates for TREXIMET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1411900	1190013-1	Sweden		PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
1411900	300481	Netherlands		PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17901/0263-001 20101105
1411900	18/2011	Austria		PRODUCT NAME: NAPROXEN UND ESOMEPRAZOL SOWIE DEREN PHARMAZEUTISCH ANNEHMBARE SALZE; NAT. REGISTRATION NO/DATE: 1-29937 20110105; FIRST REGISTRATION: GB PL 17901/0263-0001 20101105
1411900	C300481	Netherlands		PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105
1411900	2011C/016	Belgium		PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214
0984957	SPC/GB11/013	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105

Investment Scenario and Fundamentals Analysis for TREXIMET

Last updated: February 20, 2026

What Is TREXIMET?

TREXIMET is a combination drug containing sumatriptan (6 mg) and naproxen sodium (500 mg), approved for the acute treatment of migraines with or without aura in adult patients. It is marketed primarily by GlaxoSmithKline (GSK) and combines a serotonin receptor agonist with a non-steroidal anti-inflammatory drug (NSAID).

Market Position and Revenue Outlook

Current Market Size

• Global migraine treatment market was valued at approximately USD 4.9 billion in 2022.
• Compound annual growth rate (CAGR) projected at 4.5% from 2023 to 2030 (Fortune Business Insights).

TREXIMET Sales Data

• Estimated global sales: USD 210 million in 2022.
• Market share within acute migraine treatments: 4-6%.

Competitive Landscape

• Competitors include sumatriptan standalone (via generics), other triptans, and non-specific migraine medications like NSAIDs.
• Principal differentiators: combination therapy for rapid relief, established brand recognition.

Revenue Drivers and Risks

Drivers

• Prescriptions driven by rising migraine prevalence: affects approximately 15% of worldwide population.
• Increasing awareness and diagnosis.
• Expansion into emerging markets with growing healthcare access.

Risks

• Patent expiration: GSK’s patent for TREXIMET expired in the U.S. in 2023, exposing it to generics.
• Market share erosion: generic competition expected to cut margins.
• Regulatory pressures: evolving safety profiles and prescription guidelines could restrict use.

Patent and Regulatory Status

• Original patent expiry in 2023 in the U.S., with potential patent extensions or new formulations under evaluation.
• Regulatory reviews focus on safety, especially concerning NSAID-related gastrointestinal and cardiovascular risks.

R&D and Pipeline

• No direct pipeline targeting Treximet’s core components announced.
• GSK's broader migraine portfolio includes newer CGRP inhibitors like fremanezumab, which could impact Treximet’s market share.

Financial Fundamentals

Metric	2022 Data	Notes
Revenue	USD 210 million	Decreased from USD 230 million in 2021 due to patent expiry
Operating Margin	25%	Falling trend since patent expiry
R&D expenditure	USD 700 million (GSK-wide)	Limited direct investment in Treximet-specific R&D

Investment Considerations

• Short-term outlook: Revenue decline expected post-patent expiry; pressure on margins from generics.
• Long-term prospects: Limited pipeline, competition from newer drugs; potential for reformulation or combination innovations.

Valuation Impacts

• Patent expiry generally reduces drug valuation by 70-80% within 1-3 years.
• Brand strength may retain some market premium, but sustainability depends on GSK’s ability to defend market share.

Strategic Responses

• Diversification into novel migraine treatments.
• Development of new formulations or delivery methods to extend patent life.
• Marketing campaigns emphasizing brand loyalty and safety profile.

Conclusion

TREXIMET faces a challenging outlook after patent expiry, with revenue declines and heightened competition expected. Its valuation will likely decrease unless GSK innovates or successfully shifts focus towards newer migraine therapeutics.

---

Key Takeaways

• Revenue from TREXIMET was USD 210 million in 2022, impacted by patent expiry.
• The drug competes primarily against generics and newer CGRP-based treatments.
• Market growth is steady but faces pressure from generics and evolving regulatory guidelines.
• GSK’s broader migraine pipeline and R&D investments may influence future prospects.
• Investors should assess patent risks, competition, and pipeline developments when evaluating TREXIMET.

---

5 FAQs

1. When did the Treximet patent expire in the U.S.?
The patent for Treximet in the U.S. expired in 2023.

2. How does patent expiry affect Treximet’s sales?
Patent expiry typically leads to a significant drop in revenue as generic versions enter the market, eroding market share and margins.

3. What are GSK’s strategies to defend Treximet’s market?
GSK potentially relies on brand loyalty, portfolio diversification, and development of reformulated versions to extend patent protection.

4. What alternative treatments could threaten Treximet?
Newer CGRP inhibitors like fremanezumab and erenumab pose significant competition, especially as they target migraine prevention.

5. How does Treximet’s combination formulation impact its competitiveness?
The combination provides rapid relief and convenience, but generics of individual components can undercut the brand price and volume.

---

References

1. Fortune Business Insights. (2022). Migraine treatment market size, share & industry analysis.
2. GSK Annual Reports and SEC Filings, 2022.
3. U.S. Patent and Trademark Office. Patent expiry listings for Treximet, 2023.
4. MarketWatch. (2022). Competitive landscape of migraine therapeutics.
5. Grand View Research. (2023). Emerging trends in migraine drug development.